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ABSTRACT
Objectives: This study aimed to isolate the active compound of Michelia champaca L. bark and test its activity using mechanism-based yeast bioassay.
Methods: The bark was extracted by methanol; fractionation was done by liquid-liquid extraction (LLE) using n-hexane, ethyl acetate, and water. The 
activity of LLE fractions was tested by mechanism-based yeast bioassay. The most active fraction was then separated by vacuum liquid chromatography, 
further separated by classical column chromatography and purified by recrystallization. The isolate was characterized by ultraviolet-visible, infrared 
spectrophotometric method, nuclear magnetic resonance spectroscopy, and mass spectrometric method.
Results: The isolation process resulted in an isolate named MCET51. Characterization data showed that MCET51 was proved as liriodenine (C17H9NO3) 
with molecular weight 275 (m/z), an aporphine alkaloid. The activity assay showed that liriodenine was active against Saccharomyces cerevisiae strain 
1140, 1353, and 1138 with IC12 values were 22.15±1.71, 24.76±0.56, and 7.02±1.85 µg/ml, respectively.
Conclusions: It can be concluded that M. champaca L. bark contained liriodenine which was active both as topoisomerase I inhibitor and 
topoisomerase II inhibitor.
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INTRODUCTION
Michelia champaca L. or Cempaka kuning is a tree with 15-25 m high, 
grown in Java area in Indonesia, at 1200 m altitude marshy forest. 
This species is a member of Magnoliaceae that usually produces 
proanthocyanidins and alkaloid, often cyanogenic compounds and 
volatile oil. Traditional usage of bark is for tonicum, herbal maternity, 
and curing fever [1,2].
M. champaca bark was active against Aspergillus versicolor, Trichophyton 
tronsurum, Aspergillus niger, and Aspergillus vitis [3] and against human 
epidermoid carcinoma of the nasopharynx [4]. The leaves were active 
as an anti-inflammatory [5], antiarthritic [6], and antifertility [7]. 
Michelia flower was active as burn wound healing [8], antioxidant [9], 
anti-inflammatory [10], antihyperlipidemic [11], and anticancer on 
Ehrlich ascites carcinoma cell line [12]. In addition, the flower and 
leaves of Michelia were having antiulcerogenic property [13].
Chemical compounds contained in C. kuning were sinapyl 4-O-β-
D-glucopyranoside alcohol, sinapyl 4-O-β-D-glucopyranoside 
aldehyde, syringaresinol and N-acetylnonaine [14], michampanolide, 
8-acetoxyparthenolide, magnograndiolide, parthenolide, 
cestunolide [15], quercetin [16], champacaine, anonaine, norushinsunine, 
ushinsunine, N-acetylanonaine, roemerine, asimilobine, anolobine, 
isocorydine, liriodenine, atherospermidine, O-methyl moschatoline, 
syringaresinol, N-trans-feruloyltyramine, 4-hydroxybenzaldehyde, 
vanillin, vanillic acid, syringic acid, 3,4-dimethoxybenzoic acid, coniferyl 
aldehyde, syringin, scopoletin, 4-acetonyl-3,5-dimethoxy-p-quinol, 
sitostenone, stigmasta-4,22-dien-3-one [17], stigmasterol and 3β-16α-
dihydroxy-5-cholestene-21-al, Michelia-A, and guaianolides [4].
DNA topoisomerases is an important enzyme in cell proliferation phase 
of developing cancer in all types. Anticancer targeting this enzyme will 
alter the process of DNA replication and transcription so that inhibit cell 
division and inactivate cancerous cells from growing and dividing [18]. 
Mechanism of drug targeting this enzyme and biological roles of DNA 
topoisomerase can be studied in yeast, as powerful model system [19] 
because of its genetic and biochemical of yeast resemblances is close to 
mammalian cells [20]. Hence, microbial yeast bioassay is suitable for 
evaluating or screening anticancer agents.
In previous research, 23 species of Apocynaceae, Simaroubaceae, 
and Magnoliaceae have been screened for their anticancer 
activity, and M. champaca L. bark was one of the best active 
extracts against Saccharomyces cerevisiae strain 1140, 1353, and 
1138 with IC12 values were 3424.54±2806.57, 2124.42±450.40, 
and 542.6±102.45 µg/ml, respectively. The results mean that 
M. champaca extract active as anticancer, having DNA damaging agent 
or topoisomerase inhibitor [21]. However, the active ingredients that 
corresponded with the activity were still unknown. So, this present 
study aimed to isolate the active compound of M. champaca L. bark 
guided by mechanism-based yeast bioassay.
METHODS
Materials
C. kuning bark, methanol, ethanol, aquadest, n-hexane, chloroform, 
ethyl acetate, dimethyl sulfoxide, precoated plate silica gel GF254, silica 
gel H, silica gel 60 (0.063-0.200 mm), agar bacteriological, peptone, 
dextrose, yeast extract, and sodium chloride.
Instruments and apparatus
Grinder, macerator, rotavapor (Buchi), electric dryer (Philips), separatory 
funnel, freeze dryer (Telstar), vacuum column chromatography, 
classical column chromatography, common glassware in laboratory, 
ultraviolet (UV) lamp (Desaga), UV-visible spectrophotometer (HP 
8453), thin-layer chromatography (TLC) densitometer (Camag), 
infrared spectrophotometer (FT/IR Jasco 4200), mass spectrometry 
(waters), and nuclear magnetic resonantion spectrometry (Agilent 
500 MHz).
Research Article
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2016.v9i5.12856
Asian J Pharm Clin Res, Vol 9, Issue 5, 2016, 158-161
 Zuhrotun et al. 
159
Sample preparation
M. champaca L. bark was collected on January 2015 from area of Institut 
Teknologi Bandung (ITB) West Java Indonesia. Fresh bark was sorted, 
chopped in small pieces, air-dried in drying cupboard (40°C) for 24 hrs. 
Plant sample (collection no 12.130) was authentication in Herbarium 
Bandungense, School of Life Sciences and Technology ITB.
Extraction and fractionation
Extraction of dried bark was done by methanol maceration for 24 hrs 
in three replication, and the filtrate was concentrated using vacuum 
rotary vaporator. Condensed extract was fractionated by liquid-liquid 
extraction (LLE) using n-hexane followed by ethyl acetate and water. All 
fractions of LLE were tested for their activity using mechanism-based 
yeast bioassay against S. cerevisiae strain 1140, 1353, and 1138.
Activity test using mechanism-based yeast bioassay
The method mechanism-based yeast bioassay was done according 
to Gunatilaka and Kingston [20], Gunatilaka et al. [22], Subong and 
Primavera [23] as modified by Zuhrotun et al. [21] as followed. 
Saccharomyces cerevisiae strains 1140, 1353, and 1138 that cultured 
in yeast peptone dextrose (YPD) broth was suspended in sterile 
0.9% saline solution until the transmitant was 80% at l 600 nm. 
Yeast inoculums 1 ml and medium YPD agar 20 ml were poured into 
a petri dish with 9 cm diameter that produced 6 mm layer. Seven 
wells with 6 mm diameter were made on the plate using perforator. 
Samples were dissolved in a mixture of dimethyl sulfoxide-methanol 
(1:1) with variation concentrations. Amount of 50 µl of the mixture 
was placed in each well. The plates were then incubated at 30°C 
for 36-48 hrs. The samples were considered active or contain DNA 
damaging agent if inhibition zone produced as the growth of yeast 
were inhibited. IC12 value was referred to required concentration of 
sample (in µg/ml) that produced an inhibition zone of 12 mm around 
a well. The value was determined using linear regression from dose-
response curves with log of dose as absis (Y) and zone size as ordinate 
(X). A topoisomerase I inhibitor defined to sample that active against 
S. cerevisiae strain 1140 and A topoisomerase II inhibitor defined to 
sample that active against S. cerevisiae strain 1353.
TLC bioautography
To guide isolation of active compound, the active fractions were tested 
by TLC bioautography [24,25] with modification. Chromatography 
profile was performed by mixture of chloroform-methanol (9:1) as 
mobile phase and precoated plate silica gel GF254 as stationary phase. 
TLC plate was contacted on agar medium inoculated with the yeast 
for 15 minutes. After that, the plate removed and agar medium was 
incubated for 36-48 hrs, and inhibition zones were measured.
Further separation and purification
The active fraction (10.21 g) was separated using silica gel H by 
vacuum liquid chromatography with isocratic elution using n-hexane-
ethyl acetate (1:9) resulted 34 fractions. Fractions 16-31 (0.98 g) 
were further separated by open-column chromatography using silica 
gel 60 with isocratic elution of ethyl acetate-ethanol (10:1) resulted 
72 subfractions. Subfractions 18-26 (0.27 g) were subjected to 
open-column chromatography again with same conditions resulted 
in 53 subfractions. Every fraction was monitored by TLC. The last, 
subfractions 7-18 purified by recrystallization using chloroform-
methanol (9:1) and obtained yellow crystal-needle isolate (30.2 mg) 
named MCET51.
The purity of MCET51 was tested by TLC using 3 mobile phases and 
two-dimensional (2D) TLC. The chromatography performed with 
commercial precoated plate silica gel GF254 as solid phase and mixture 
of ethyl acetate-ethanol (10:1), ethyl acetate-chloroform (6:4), and 
chloroform-methanol (9:1) as mobile phase.
Characterization of isolate
Characterization of MCET51 was done by color test, UV-visible, infrared 
spectrophotometric method, mass spectrometric method and nuclear 
magnetic resonance (NMR) spectroscopy of proton (1H), carbon (13C), 
Heteronuclear Single Quantum Coherence and heteronuclear multiple-
bond correlation spectroscopy.
RESULTS AND DISCUSSION
The yield of extraction was 5.82% (w/w). Since M. champaca bark 
extract was reported active with the method [21], then it directly 
fractionated by LLE obtained n-hexane, ethyl acetate, and water 
fractions. All fractions were tested by mechanism-based yeast bioassay 
to S. cerevisiae strains 1140, 1353, and 1138. Activity results of fractions 
were shown in Table 1.
Fractions and pure compounds were considered active if IC12 values 
at the lower doses of the extract, where the active extract ranging 
from 1000 to 8000 µg/ml [20]. Table 1 showed that all fractions were 
active against S. cerevisiae strain 1353 and 1138 with IC12 values 
<8000 µg/ml and n-hexane fraction also active against S. cerevisiae 
strain 1140. These results indicated that the fractions contain active 
compound as topoisomerase inhibitor.
TLC bioautography is a combination of TLC as simple separation 
technique and antimicrobial bioassay. In this research, TLC was used to 
separated quickly the mixture of compounds contained in LLE fractions 
so that can be readily tested the biological activity of each component 
(spot). The result of TLC bioautography showed that the Rf of the active 
compounds were 0.8-0.84 of ethyl acetate fraction and 0.69-0.74 of 
n-hexane fraction.
According to TLC bioautography results, further separation and 
purification were focus on the active spot in ethyl acetate fraction. The 
process was yielded yellow crystal-needle isolate named MCET51. 
Purity tests showed MCET51 was a single spot with an area under 
curve 95.25% at 200-700 nm. The isolate had a melting point at 
271.5-272.6°C.
The MCET51 gave yellow-red with Dragendorff reagent indicated that 
was alkaloid. UV-vis spectrum showed peaks absorbance at 205, 248, 
268, 309, and 414 nm in methanol that predicted MCET51 was identical 
to aporphine alkaloid [17,26]. Infrared spectrum showed existence 
functional group of amines at 3421.1/cm, C-H stretch at 3039.26/cm 
and 2919.7/cm, carbon aromatic at 1658.48, 1573.63; 1473.35 and 
1419.35/cm, and carbonyl at 1307.5/cm [27]. Mass spectrum showed 
100% peak ion [M+1]+ 276.14 (m/z), mean that molecular weight of 
MCET51 was 275 (m/z).
NMR spectrum signals of MCET51 in CDCl3 showed the number of 
proton and carbon with their 2D correlation in determining structural 
arrangement [27] as shown in Table 2. These spectrum signals were 
identical with liriodenine based on previous results [26,28,14]. Based on 
characterization, data showed that MCET51 was proved as liriodenine, 
an aporphine alkaloid with molecular formula was C17H9NO3.
The result of activity assay of isolate showed that liriodenine was 
active against S. cerevisiae strain 1140 (IC12 22.15±1.71 µg/ml), strain 
Table 1: The IC12 values (µg/ml) of fractions as results of activity 
test using mechanism-based yeast bioassay











S. cerevisiae: Saccharomyces cerevisiae
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1353 (IC12 24.76±0.56 µg/ml), and strain 1138 (IC12 7.02±1.85 µg/ml). 
It means that liriodenine is active both as topoisomerase I inhibitor 
and topoisomerase II inhibitor. These IC12 values of isolate were lower 
than M. champaca bark extract [21] and LLE fractions and mean that 
isolate more potent than the extract and fractions. Hence, it was clearly 
defined that liriodenine was an active ingredient of M. champaca as an 
anticancer agent or topoisomerase inhibitor.
This research results reported that based on mechanism-based yeast 
bioassay M. champaca L. fractions and liriodenine were proved as Type I 
and Type II topoisomerase inhibitor, whereas other studies only showed 
liriodenine as topoisomerase II inhibitor. Activity test of liriodenine by 
in vivo assay using SV40-infected cells and in vitro enzymatic assay 
reported that liriodenine is a potent inhibitor of topoisomerase II [29]. 
Computational study of liriodenine by molecular modeling and docking 
technique reported that liriodenine is the most effective aporphine 
alkaloids as a novel inhibitor of topoisomerase II [30]. Combination 
studies by in silico absorption, distribution, metabolism, and excretion 
toxicology analysis, docking and molecular dynamic simulation of 
100 anticancerous alkaloids reported that liriodenine as one of six 
alkaloids inhibited topoisomerase II [18].
CONCLUSIONS
Our research revealed that M. champaca L. bark fractions active as 
topoisomerase inhibitor. Isolation from ethyl acetate fraction guided by 
mechanism-based yeast bioassay carried out liriodenine that active as 
topoisomerase I inhibitor and topoisomerase II inhibitor.
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